menu
    • menu
    [{"orgOrder":0,"company":"Rapafusyn Pharmaceuticals","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"ONC-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Rapafusyn Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Rapafusyn Pharmaceuticals \/ BioTrack Capital","highestDevelopmentStatusID":"2","companyTruncated":"Rapafusyn Pharmaceuticals \/ BioTrack Capital"},{"orgOrder":0,"company":"Rapafusyn Pharmaceuticals","sponsor":"3E Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Rapafusyn Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Rapafusyn Pharmaceuticals \/ 3E Bioventures","highestDevelopmentStatusID":"2","companyTruncated":"Rapafusyn Pharmaceuticals \/ 3E Bioventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Rapafusyn Pharmaceuticals

    Menu

    Rapafusyn Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rapafusyn Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Rapafusyn Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONC-001

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : BioTrack Capital

                            Deal Size : $44.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Rapafusyn Closes Over-Subscribed $44 Million Series A Financing

                            Details : The financing accelerates the advancement of Rapafusyn’s broad drug pipeline addressing many diseases of high unmet medical need in the oncology, immunology, renal and pain disease areas.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 04, 2025

                            Lead Product(s) : ONC-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : BioTrack Capital

                            Deal Size : $44.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rapafusyn Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Rapafusyn Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : 3E Bioventures

                            Deal Size : $28.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Rapafusyn Pharmaceuticals Secures $28 Million Series A for Molecular Glue Drug Discovery

                            Details : The financing will propel the progress of Rapafusyn's innovative and diverse pipeline of macrocyclic peptide-based non-degrading molecular glues for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : 3E Bioventures

                            Deal Size : $28.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth